Core Insights - Zoetis (ZTS) shares have decreased by 24.8% year to date due to safety concerns regarding its monoclonal antibody therapies for osteoarthritis in dogs and cats, namely Librela and Solensia, which are significant revenue sources for the company [1][8] - The FDA raised alarms about Librela in late 2024 after adverse event reports indicated serious neurologic effects and other health issues in dogs, including seizures and even death [2][3] - An analysis revealed that dogs treated with Librela reported musculoskeletal adverse events at approximately nine times the rate of other osteoarthritis therapies, raising further safety concerns [4][5] - Consequently, Librela and Solensia experienced year-over-year sales declines in the second and third quarters of 2025, leading Zoetis to revise its full-year revenue guidance down to $9.4-$9.475 billion from a previous range of $9.45-$9.6 billion [6][8] Sales and Financial Performance - Librela and Solensia's sales declines have pressured Zoetis' stock, which has fallen 29.9% over the past year, contrasting with a mere 0.3% decline in the industry [7][8] - Despite the challenges in the osteoarthritis segment, Zoetis is seeing strong performance in its parasiticides and dermatology portfolios, which are helping to mitigate some of the revenue losses [9][12] Future Outlook - Zoetis is planning for a potential rebound in 2026 by expanding its product offerings, including new long-acting therapies for osteoarthritis, which aim to enhance treatment adherence and broaden market uptake [11][12] - The company has received approvals for new products like Lenivia and Portela, which are designed to complement existing therapies and provide veterinarians with more treatment options [11][12]

These companies' prospects are better than recent performances may suggest.Recent developments have led to significant declines in the stock prices of Pinterest (PINS +2.15%) and Zoetis (ZTS +0.38%). Due to company-specific issues, both are currently not that far from their 52-week lows. The good news, though, is that Pinterest and Zoetis may be able to recover from their recent woes and deliver strong returns over the long run, which would make them steals at current levels.Let's examine why these companie ...

Core Insights - The animal health industry is facing challenges that require companies to innovate and adapt strategically [1] - Zoetis Inc. (NYSE:ZTS) is under scrutiny from KeyBanc Capital Markets regarding its product lineup and market positioning [2] - KeyBanc initiated coverage on Zoetis, highlighting ongoing challenges from its osteoarthritis (OA) pain monoclonal antibody (mAb) products and increased competition [3] Company Performance - Zoetis is experiencing headwinds from its OA pain mAb products, which have faced criticism on social media for potential side effects [4] - Despite these challenges, Zoetis is recognized for its history of innovation and is considered a high-quality company with revenue growth rates above the industry average and historically high profit margins [5] - The company reported third-quarter sales of $2.4 billion, reflecting a 1% year-over-year increase, slightly below the consensus estimate of $2.41 billion [6] Market Positioning - KeyBanc has assigned a Sector Weight rating to Zoetis until there is significant improvement in its OA pain mAb products or new high-revenue product launches [6] - Zoetis shares are currently trading at approximately 17.5x forward P/E, which is a discount compared to its two-year average of around 27x [6] - Growth in parasiticides, diagnostics, and dermatology portfolios was offset by a decline in mAb products for OA pain [7]

Core Insights - Zoetis Inc. is a leading company in the animal health industry, offering a variety of products and services for both pets and livestock, with a focus on innovative solutions in parasiticides, diagnostics, and dermatology [1] Financial Performance - In Q3 2025, Zoetis reported an adjusted earnings per share (EPS) of $1.70, exceeding the consensus estimate of $1.62 [2][6] - The adjusted net income for the company reached $754 million, marking a 5% increase on a reported basis and a 9% rise on an organic operational basis [3] - Total sales for Zoetis amounted to $2.4 billion, reflecting a 1% year-over-year increase, although slightly below the expected $2.41 billion [3] Market Position and Challenges - Despite facing challenges with monoclonal antibody products for osteoarthritis pain, such as Librela and Solensia, which saw a decline in sales, Zoetis continues to maintain a strong market presence [4][6] - Sales of livestock products decreased by 9% due to the divestiture of the medicated feed additive product portfolio [4] - The stock price for Zoetis is currently at $126.06, down approximately 12.67% from its previous high, with a market capitalization of around $55.87 billion [5]

Core Insights - Zoetis, Inc. (ZTS) reported third-quarter 2025 adjusted earnings of $1.70 per share, exceeding the Zacks Consensus Estimate of $1.62, while total revenues grew 1% year over year to $2.4 billion, missing the estimate of $2.41 billion [1][7] Financial Performance - U.S. revenues decreased 2% year over year to $1.32 billion, missing both the Zacks Consensus Estimate of $1.34 billion and the model estimate of $1.38 billion [3][7] - Sales of companion animal products in the U.S. remained flat at $1.07 billion, with growth in parasiticides and dermatology products offset by declines in monoclonal antibody products for osteoarthritis pain [4][7] - Livestock product sales in the U.S. fell 9% to $253 million, primarily due to the divestiture of the medicated feed additive product portfolio [6][9] International Segment - Revenues from the International segment increased 3% year over year to $1.06 billion, surpassing the Zacks Consensus Estimate of $1.04 billion [8] - Ex-U.S. sales of companion animal products rose 8% to $583 million, driven by growth in key products [9] Guidance and Future Outlook - Zoetis has cut its 2025 revenue guidance to $9.4-$9.475 billion from a previous range of $9.45 billion to $9.6 billion, while maintaining adjusted earnings guidance of $6.30-$6.40 per share [10] - The company secured a positive opinion for Lenivia, a long-acting monoclonal antibody therapy for canine osteoarthritis pain, with a final European decision expected in late 2025 [11][13]

Financial Data and Key Metrics Changes - The company reported $2.4 billion in revenue for Q3 2025, growing 1% on a reported basis and 4% on an organic operational basis, primarily driven by price, as volume was flat [19][5][15] - Adjusted net income was $754 million, reflecting a 5% increase on a reported basis and a 9% increase on an organic operational basis [19][30] - Adjusted gross margins improved to 71.6%, growing 90 basis points on a reported basis [29][30] Business Line Data and Key Metrics Changes - The global companion animal portfolio generated $1.7 billion in revenue, growing 2% operationally, with the parasiticide franchise contributing $356 million (7% growth) and key dermatology posting $469 million (3% growth) [20][19] - The osteoarthritis (OA) pain franchise declined 11% operationally to $138 million, with Librela sales down 15% globally [20][10] - The global livestock portfolio grew 10% on an organic operational basis, contributing $725 million in revenue [20][13] Market Data and Key Metrics Changes - In the U.S., revenue decreased 2% on a reported basis but increased 3% on an organic operational basis, with companion animal flat and livestock growing 14% [21][19] - International revenue grew 3% on a reported basis and 6% on an organic operational basis, with companion animal growing 4% and livestock growing 8% [26][19] Company Strategy and Development Direction - The company is focused on a multi-pronged strategy to return Librela to growth, including increasing awareness of OA as a serious disease and deepening education with specialists and veterinarians [10][11] - The company is evolving its U.S. commercial structure to enhance agility and efficiency, aiming for a leaner field organization [12][13] - The company anticipates a major new market approval each year for the next several years, highlighting its robust innovation pipeline [11][16] Management's Comments on Operating Environment and Future Outlook - Management noted that therapeutic visits have been declining, impacting new patient starts, and emphasized the importance of addressing this trend for future growth [36][66] - The company remains confident in its long-term growth trajectory, supported by a diversified portfolio and strong market fundamentals [15][31] - Management updated full-year guidance, revising organic operational revenue growth to a range of 5.5%-6.5% [15][30] Other Important Information - The company announced the retirement of Rob Polzer, head of R&D, and the appointment of Kevin Esch as his successor [17][16] - The company is investing in manufacturing excellence to support its expanding portfolio, including a new biologics facility [12][11] Q&A Session Summary Question: What changed interquarterly after raising guidance last quarter? - Management noted anticipated deceleration in the second half of the year, competitive launch dynamics, and macro impacts on U.S. clinics as key factors [35][36] Question: How is the competitive landscape affecting the dermatology category? - Management acknowledged competitive pressures but emphasized that patient share gains from competitors have been limited [42][66] Question: What is the outlook for therapeutic visits and when might recovery occur? - Management indicated that therapeutic visits have been declining, impacting patient starts, and recovery timing remains uncertain [66][63] Question: How durable are the growth drivers in livestock? - Management expressed confidence in the sustainability of livestock growth driven by increased protein demand and urbanization trends [72][71] Question: What lessons have been learned from Librela's launch for upcoming products? - Management plans to apply learnings from Librela to new launches, focusing on education and awareness of OA [58][57]

Core Insights - Zoetis, Inc. (ZTS) is anticipated to exceed expectations in its third-quarter 2025 earnings report, scheduled for November 4, 2025, with revenue estimates at $2.41 billion and earnings per share (EPS) at $1.62 [1][5] Group 1: Revenue Sources - The company generates most of its revenue from a diverse portfolio of veterinary medicines and vaccines for livestock and companion animals, with additional income from non-pharmaceutical categories such as nutritional products and precision animal health services [2] - Revenue from the U.S. segment is projected to increase, primarily due to rising sales of companion animal products, with estimates at $1.34 billion according to Zacks Consensus and $1.38 billion based on internal models [3] - The International segment is also expected to see revenue growth, driven by higher sales of companion animal products, with estimates of $1.04 billion from Zacks and $1.03 billion from internal models [4] Group 2: Product Performance - Companion animal products, particularly Simparica Trio, Apoquel, and Cytopoint, are expected to significantly contribute to revenue growth in both U.S. and International segments [5][7] - However, sales of monoclonal antibody products for osteoarthritis, Librela and Solensia, are likely to decline in the U.S. due to concerns over side effects [8] - The FDA's recent approval of a new indication for Simparica Trio is expected to further enhance sales by preventing flea tapeworm infections [9] Group 3: Livestock Products - Livestock product sales in both U.S. and International segments are anticipated to decline due to the divestiture of certain product lines, including medicated feed additives and water-soluble products [10] Group 4: Earnings Surprise History - Zoetis has a strong earnings surprise history, having surpassed estimates in the last four quarters with an average surprise of 6.19%, including an 8.64% surprise in the most recent quarter [11][12] Group 5: Earnings Prediction - The company's earnings model indicates a likely earnings beat, supported by a positive Earnings ESP of +0.32% and a Zacks Rank of 3 [13]

Core Insights - Zoetis Inc. is a global leader in animal health with a market cap of $64.3 billion, focusing on medicines, vaccines, diagnostics, and precision health products for livestock and companion animals [1] Financial Performance - The company is expected to announce fiscal Q3 2025 results on Nov. 4, with analysts predicting an adjusted EPS of $1.62, a 2.5% increase from $1.58 in the same quarter last year [2] - For fiscal 2025, adjusted EPS is projected to be $6.35, reflecting a 7.3% rise from $5.92 in fiscal 2024, with further growth anticipated to $6.87 in fiscal 2026, an 8.2% year-over-year increase [3] Stock Performance - Over the past 52 weeks, Zoetis shares have declined by 22.9%, underperforming the S&P 500 Index, which increased by 15.3%, and the Health Care Select Sector SPDR Fund, which saw a 4.1% decline [4] - Despite reporting better-than-expected Q2 2025 adjusted EPS of $1.76 and revenue of $2.5 billion, shares fell by 3.8% due to weaknesses in certain product lines, including a 21% drop in U.S. livestock product sales [5] Analyst Ratings - The consensus rating for Zoetis stock is bullish, with a "Strong Buy" rating from 11 out of 16 analysts, one "Moderate Buy," and four "Hold" ratings. The average price target is $192.50, indicating a potential upside of 31.2% from current levels [6]

Core Insights - Zoetis, Inc. (ZTS) reported second-quarter 2025 adjusted earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.62 and up from $1.56 in the same quarter last year [1] - Total revenues for the quarter reached $2.46 billion, a 4% year-over-year increase, surpassing the Zacks Consensus Estimate of $2.40 billion and the previous year's revenue of $2.36 billion [1] Revenue Breakdown - The U.S. segment revenues increased by 4% year over year to $1.36 billion, beating both the Zacks Consensus Estimate of $1.33 billion and the model estimate of $1.31 billion [2] - Sales of companion animal products in the U.S. rose by 9% to $1.18 billion, driven by products like Simparica Trio and key dermatology items, although this was partially offset by a decline in monoclonal antibody sales for osteoarthritis pain [3] - International segment revenues grew by 3% year over year to $1.07 billion, exceeding the Zacks Consensus Estimate of $1.05 billion [7] - Ex-U.S. sales of companion animal products increased by 8% to $612 million, supported by growth in various key products [8] - Livestock product sales in the U.S. decreased by 21% to $180 million, primarily due to the divestiture of the medicated feed additive product portfolio [5] Future Guidance - Zoetis raised its 2025 adjusted earnings outlook to a range of $6.30-$6.40 per share, up from the previous range of $6.20-$6.30 [10] - Revenue guidance for 2025 was also increased to $9.45-$9.6 billion from the earlier range of $9.425 billion to $9.575 billion [10]

Financial Performance - Revenue reached $2.46 billion, a 4% increase compared to the previous year[47] - Adjusted Net Income was $783 million, representing a 10% year-over-year increase[47] - Adjusted Diluted EPS increased to $1.76, a 13% rise compared to the previous year[47] - The company is raising its 2025 revenue outlook to $9450 million - $9600 million[23] - The company is raising its 2025 adjusted net income outlook to $2825 million - $2875 million[23] - The company is raising its 2025 adjusted diluted EPS outlook to $630 - $640[23] Segment Performance - U S segment revenue totaled $1.4 billion, with 7% organic operational growth[20] - U S Companion Animal revenue reached $1.2 billion, a 9% year-over-year increase[20] - International segment revenue amounted to $1.1 billion, showing 9% organic operational growth[20] - International Livestock revenue grew by 10% on an organic operational basis[20] Product Performance - The Simparica franchise experienced 17% operational growth, with revenue reaching $448 million[29] - The Key Dermatology franchise grew by 11% operationally, with revenue reaching $460 million[34] - Livestock revenue increased by 6% on an organic operational basis, reaching $631 million (excluding MFA revenue)[44]